| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Antares Pharma, Inc. > News item |
Antares says TecTix enhances drug absorption, reduces skin irritation
By Elaine Rigoli
Tampa, Fla., April 24 - Antares Pharma, Inc. announced Monday the development of the TecTix drug-delivery system for topical and transmucosal delivery of active pharmaceutical agents.
The TecTix system is based on transiently reducing the melting point of an active drug by using a combination of known chemical compounds as special permeation enhancers.
Reducing the melting point of a drug with TecTix typically results in increased skin permeation, which in the near term should allow Antares to develop novel products specifically targeted for proprietary dermatological and mucosal delivery applications, according to a news release.
"The very promising results obtained from preclinical testing support our belief that the TecTix system can be successfully applied to numerous therapeutic areas. As a substantially alcohol-free delivery system, TecTix appears to be a perfect match for dermatological products targeting different layers of the skin or mucosa, without utilizing potentially irritating excipients," managing director Dario Carrara said in the release.
TecTix has been tested in-vitro on numerous drug models, including AP-1118, a local anesthetic where concentration in the dermis was increased by 236%, improving the topical to systemic absorption ratio.
The benefits of TecTix were also confirmed in AP-1110, another local skin anesthetic, where the melting point was decreased by more than 50 degrees celsius, causing it to melt spontaneously at room temperature.
The company said it has filed patent applications for the TecTix system.
Antares Pharma, with headquarters in Exton, Pa., is a specialized product-development company focused on developing patented drug-delivery systems and injectable-device engineering capabilities.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.